Showing 7231-7240 of 9923 results for "".
- MELA Sciences Appoints Rose Crane as President and Chief Executive Officer and a Directorhttps://practicaldermatology.com/news/20131106-mela_sciences_appoints_rose_crane_as_president_and_chief_executive_officer_and_a_director/2459422/MELA Sciences, Inc. (MELA), the medical device company that has developed and is commercializing MelaFind(R), an optical diagnostic device using proprietary technology that enables dermatologists to “see” below the surface of a patient's skin to aid in the diagnosis of melanoma, today announced that
- Suneva Medical Announces Expansion Of Its ReGenica Distribution Partnership With Obagi Medical Productshttps://practicaldermatology.com/news/20131101-suneva_medical_announces_expansion_of_its_regenica_distribution_partnership_with_obagi_medical_product/2459424/Suneva Medical, Inc., recently announced plans to expand its existing partnership with Obagi Medical Products, Inc. Suneva Medical distributes, and is the exclusive licensee for, the full line of ReGenica skincare produ
- Subliminally Exposed to be Presented at Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20131029-subliminally_exposed_to_be_presented_at_cosmetic_surgery_forum/2459426/Based on the New York Times and USA Today best seller, Subliminally Exposed, Dr. Steven Dayan and Valerie Monroe will present at this year's Cosmetic Surgery Fo
- New Stelara Data Show Inhibition Of Joint Destruction In Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/20131029-new_stelara_data_show_inhibition_of_joint_destruction_in_psoriatic_arthritis_patients/2459427/New findings from two integrated Phase III Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with ustekinumab (Stelara) resulted in
- Restoration Robotics Announces the Launch Of ARTAS Hair Studio™https://practicaldermatology.com/news/20131025-restoration_robotics_announces_the_launch_of_artas_hair_studio/2459428/At this year's International Society of Hair Restoration Surgery (ISHRS) conference in San Francisco (October 23-27), Restoration Robotics will introduce the ARTAS Hair Studio™, a new product that expands the clinical indication and capability o
- Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticumhttps://practicaldermatology.com/news/20131024-auxilium_pharmaceuticals_inc_announces_first_patient_dosed_in_phase_2a_cellulite_study_of_collegenase_clostridium_histolyticum/2459430/Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known
- Novartis Announced Positive Phase III Psoriasis Results for Secukinumabhttps://practicaldermatology.com/news/20131021-novartis_announced_positive_phase_iii_psoriasis_results_for_secukinumab/2459432/Novartis announced results from its head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to etanercept (Enbrel) in moderate-to-severe
- Humira Found Effective for Hidradentis Suppurativahttps://practicaldermatology.com/news/20131011-humira_found_effective_for_hidradentis_suppurativa/2459436/Results from a post-hoc analysis of an investigational Phase II study found that Humira (adalimumab, AbbVie) induced significant response rate in adult patients with moderate to severe hidradenitis suppurativa (HS) after 16 weeks of therapy. Researchers used the HS-Physician Global Assessment (HS-P
- FDA Files sBLA for Xolair in Patients with Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20131011-genentech_files_sbla_for_xoliar_in_patients_with_cronic_idiopathic_urticaria/2459437/The FDA accepted and filed Genentech's supplemental Biologics License Application (sBLA) for subcutaneous use of Xolair® (omalizumab) in people with Chronic Idiopathic Urticaria (CIU) who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. The filing was primarily
- Ellzey Coding Solutions Introduces ICD-10 for Dermatology Manualhttps://practicaldermatology.com/news/20131010-ellzey_coding_solutions_introduces_icd-10_for_dermatology_manual/2459440/Ellzey Coding Solutions, Inc., recently released an ICD-10 coding manual specifically for dermatologists. The 2014 ICD-10 for Dermatology program is a tool that can be used to prepare dermatologists and staff with what they need to know about the ICD-10-CM diagnosis coding syste